Independent
Tenure on this board
1.1 yrs
Meeting calendar
KMTS · Annual meeting · Wednesday, September 3, 2025
Kestra Medical Technologies Ltd
2 nominees · 3 ballot items.
Kestra Medical Technologies, Ltd. seeks shareholder approval for three matters: two Class I director elections, ratification of PwC as the company’s independent registered public accounting firm for the 2026 fiscal year, and approval of the 2025 Kestra ESPP; all three are management proposals with the board recommending voting FOR.
Market cap
$1.5B
1Y TSR
+12.7%
Board grade
C-
Record date
Jul 7, 2025
Filing
DEF 14A
Meeting concluded · Sep 3, 2025
Follow how the vote landed and what changed on Kestra Medical Technologies Ltd’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors (Class I
ManagementBoard: FORElect Conor Hanley and Elizabeth Kwo to serve as Class I directors until the Company’s 2028 annual meeting and until their successors are duly elected and qualified; the Board has nominated two directors to serve and has indicated these individuals will fill Class I seats.
- 2
Ratification of Selection of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2026; PwC audited Kestra’s financial statements in prior years and is expected to attend the meeting to respond to questions.
- 3
Approval of 2025 Employee Stock Purchase Plan
ManagementBoard: FORApprove the Kestra Medical Technologies, Ltd. 2025 Employee Stock Purchase Plan (ESPP), including a Section 423 component and a Non-Section 423 component, with initial reserve of 500,000 shares and annual evergreen adjustments; plan aims to attract, retain and motivate employees.
Director elections
Nominees on the ballot2
Independent
Tenure on this board
0.8 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BAIN CAPITAL INVESTORS LLC | 43.1% | 25,172,338 | $668M |
| 2 | FMR LLC | 8.5% | 4,971,577 | $132M |
| 3 | PRICE T ROWE ASSOCIATES INC /MD/ | 7.4% | 4,339,007 | $115M |
| 4 | Andera Partners | 4.4% | 2,540,106 | $67M |
| 5 | Yu Fan | 3.9% | 2,282,519 | $61M |
| 6 | BROWN ADVISORY INC | 2.8% | 1,614,714 | $43M |
| 7 | ALLIANCEBERNSTEIN L.P. | 2.4% | 1,426,055 | $38M |
| 8 | Omega Fund Management, LLC | 2.4% | 1,373,591 | $36M |
| 9 | EVENTIDE ASSET MANAGEMENT, LLC | 2.2% | 1,269,651 | $34M |
| 10 | VANGUARD GROUP INC | 2.0% | 1,149,486 | $30M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Kestra Medical Technologies Ltd’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.9B
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$2.0B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.2B
Esperion Therapeutics IncESPR
Special meeting·Jul 8, 2026·$814M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Reference
Frequently asked questions
- When is the Kestra Medical Technologies Ltd 2025 annual meeting?
- Kestra Medical Technologies Ltd (KMTS) holds its 2025 annual shareholder meeting on Wednesday, September 3, 2025.
- What is the record date for the Kestra Medical Technologies Ltd 2025 meeting?
- The record date for the Kestra Medical Technologies Ltd 2025 meeting is Monday, July 7, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Kestra Medical Technologies Ltd's 2025 meeting?
- The board is presenting 2 director nominees at the Kestra Medical Technologies Ltd 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Kestra Medical Technologies Ltd 2025 meeting?
- Shareholders will vote on 3 proposals at the Kestra Medical Technologies Ltd 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.